News | February 02, 2012

New Data for Symphony Presented at Society of Thoracic Surgeons 2012



February 2, 2012 — Abiomed Inc. announced that initial clinical data from the safety study for Symphony was presented by Renzo Cecere, M.D., FRCSC, FACS, associate professor of surgery at McGill University, during the late-breaking clinical trials session at the Society of Thoracic Surgeons (STS) 2012 meeting in Fort Lauderdale, Fla.

The presentation, Initial Safety Trial of an Implantable, Synchronous, Partial Circulatory Support Device: Symphony,” discussed the initial clinical data from the Symphony safety trial being conducted outside of the United States, and was presented during one of the four late-breaking clinical trials sessions at the STS meeting.

The presentation included analysis of the initial first-in-man experience, originally announced in December 2011, which demonstrated feasibility of the synchronized, implantable heart pump Symphony. The analysis indicated a marked improvement in cardiac output, improved renal function, short intensive care unit (ICU) stay and early patient mobility post implant.

“The concept of a minimally invasive implantable pump for patients in chronic heart failure, coupled with the ability to remodel the heart, is unique and groundbreaking and we are very pleased with the initial findings of Symphony,” said Cecere.

Symphony is designed to treat approximately 90,000 of the 1.6 million New York Heart Association (NYHA) Class III chronic heart failure patients by improving patient hemodynamics and potentially quality of life. The device is designed with the primary goal of lowering hospital costs by stabilizing the progression of heart failure and/or recovering/remodeling the heart.

Symphony is not currently approved for use in the United States.

For more information:

Related Content

Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure| October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Cardiovascular Risk Significantly Higher in Women With Fatty Liver Disease
News | Womens Healthcare| October 20, 2017
Nonalcoholic fatty liver disease (NAFLD) is associated with significantly higher risk of subsequent cardiovascular...
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Overlay Init